Drugs by condition
Drugs approved for diabetic macular edema
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
14
Still marketed, NDA or BLA
Drug classes
3
Novel drugs
4
New molecular entities and new biologics
In development
20
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for diabetic macular edema.
All approved drugs for diabetic macular edema, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Vascular Endothelial Growth Factor Inhibitor (9)
- Eylea Aflibercept · Regeneron Pharmaceuticals · 2011
- Lucentis Ranibizumab · Genentech · 2006
- Pavblu Aflibercept-Ayyh · Amgen INC · 2026
- Enzeevu Aflibercept-Abzv · Sandoz INC · 2026
- Nufymco Ranibizumab-Leyk · Formycon AG · 2025
- Yesafili Aflibercept-Jbvf · Biocon Biologics INC · 2024
- Eylea Hd Aflibercept · Regeneron Pharmaceuticals · 2023
- Cimerli Ranibizumab-Eqrn · Sandoz INC · 2022
- Susvimo Ranibizumab · Genentech INC · 2021
Corticosteroid (2)
Class not listed in FDA's data (3)
Drugs in development for diabetic macular edema
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- 4D-1503E10 vg, eyePhase 35 trials
4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
- TiespectusEYE201, MK-8748Phase 35 trials
EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization
- EYP-1901Phase 34 trials
EyePoint Pharmaceuticals, Inc. · Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
- OLN324Phase 34 trials
Ollin Biosciences, Inc. · Diabetic Macular Edema (DME), Wet Age Related Macular Degeneration, Wet Age-related Macular Degeneration
- RemigromigEYE103, RestoretPhase 33 trials
EyeBiotech Ltd. · Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
- BAT5906Phase 32 trials
Bio-Thera Solutions · Diabetic Macular Edema (DME), Neovascular (Wet) Age-related Macular Degeneration
- OCS-01Phase 32 trials
Oculis · Diabetic Macular Edema
- Tabirafusp tedromerKSI-501Phase 32 trials
Kodiak Sciences Inc · Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration
- AVT29proposed aflibercept HD biosimilarPhase 31 trial
Alvotech Swiss AG · Diabetic Macular Edema
- Intravitreal RanibizumabPhase 31 trial
Roche (Genentech) · Diabetic Macular Edema
- RC28-EPhase 31 trial
RemeGen Co., Ltd. · Diabetic Macular Edema (DME), wAMD
- BGE-102Phase 22 trials
BioAge Labs, Inc. · Diabetic Macular Edema (DME), Obesity and Cardiovascular Risk
- KHK4951Phase 22 trials
Kyowa Kirin Co., Ltd. · Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
- BI 3812465Phase 21 trial
Boehringer Ingelheim · Diabetic Macular Edema
- CU06-1004Phase 21 trial
Curacle Co., Ltd. · DME, Diabetic Macular Edema, Diabetic Macular Edema (DME)
- ENN0403Phase 21 trial
EnnovaBio · Diabetic Macular Edema (DME)
- INV-102Phase 21 trial
Invirsa, Inc. · Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy
- OXU-001DEXAspheresPhase 21 trial
Oxular Limited · Diabetic Macular Edema
- RO7446603Phase 21 trial
Roche (Genentech) · Diabetic Macular Edema
- SNP318Phase 21 trial
SciNeuro · Diabetic Macular Edema, DME
More on diabetic macular edema: recruiting trials · published research
Related in ophthalmology: Wet macular degeneration · Glaucoma · Dry eye disease · Geographic atrophy
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.